scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM199903113401004 |
P698 | PubMed publication ID | 10072411 |
P2093 | author name string | Schuster M | |
Walsh TJ | |||
Schwartz C | |||
Finberg RW | |||
Greenberg RN | |||
Holcenberg JS | |||
Pappas P | |||
Arndt C | |||
Seibel N | |||
Bodensteiner D | |||
Hiemenz J | |||
Dummer S | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | amphotericin B | Q412223 |
P304 | page(s) | 764-771 | |
P577 | publication date | 1999-03-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | |
P478 | volume | 340 |
Q34114674 | 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer |
Q43602550 | A 34-year-old man with lingual tumor. Lingual leishmaniasis in a patient with HIV infection |
Q34335250 | A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America |
Q35987403 | A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. |
Q38049498 | A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, As |
Q39328808 | A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia. |
Q40614209 | A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer |
Q33922242 | A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host |
Q46200207 | A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. |
Q40612309 | A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group |
Q34422191 | A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. |
Q34294925 | A strategy for managing fungal infections in haematopoietic stem cell transplantation |
Q35179541 | A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. |
Q33825563 | Advances in antimicrobial therapy |
Q34312351 | Advances in treating acute myeloid leukemia |
Q48202890 | Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations |
Q36042366 | Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis |
Q83172302 | Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis |
Q33874835 | Agents for treatment of invasive fungal infections |
Q38872275 | AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy |
Q36826922 | Amphotericin B and coccidioidomycosis |
Q44400535 | Amphotericin B and its lipid formulations |
Q34294886 | Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. |
Q34764830 | Amphotericin B and liver function |
Q24187699 | Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function |
Q38111293 | Amphotericin B formulations: a comparative review of efficacy and toxicity |
Q24193811 | Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia |
Q30887348 | Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia |
Q34294904 | Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? |
Q37854727 | Amphotericin B use in children: conventional and lipid-based formulations |
Q46277655 | Amphotericin B used as a continuous infusion is safer. |
Q40605942 | Amphotericin B--not so terrible |
Q44527998 | Amphotericin B: time for a new "gold standard". |
Q36724783 | An update on the use of antifungal agents |
Q37684378 | Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity |
Q28080147 | Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients |
Q38858839 | Antifungal agents and liver toxicity: a complex interaction |
Q36111677 | Antifungal chemotherapeutics |
Q34807486 | Antifungal drug resistance to azoles and polyenes |
Q30653666 | Antifungal drugs in the treatment of systemic candidiasis: susceptibility to antifungal drugs, drug resistance, pharmacological data |
Q37009912 | Antifungal management in cancer patients |
Q34083129 | Antifungal pharmacodynamics: review of the literature and clinical applications |
Q37727168 | Antifungal prophylaxis and treatment in patients with hematological malignancies |
Q33289645 | Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study |
Q35897495 | Antifungal therapy and outcomes in infants with invasive Candida infections |
Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
Q36591360 | Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection |
Q24239978 | Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections |
Q24243629 | Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections |
Q37873552 | Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy |
Q33659379 | Antiinfectives update: focus on treatment and prevention of viral and associated infections |
Q38202581 | Antimicrobial agents, drug adverse reactions and interactions, and cancer |
Q88495615 | Análisis de Costo Efectividad de Estrategias de Tratamiento Antimicótico en Pacientes con Neutropenia Febril Persistente y Tratamiento Antibiótico de Amplio Espectro |
Q38040820 | Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? |
Q33899108 | Aspergillosis in bone marrow transplant recipients. |
Q35038459 | Aspergillosis. Pathogenesis, clinical manifestations, and therapy |
Q35022494 | Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress? |
Q36382134 | Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America |
Q37641383 | Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex |
Q89551883 | Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies |
Q34073422 | Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation |
Q36463811 | Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis |
Q40501860 | Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies |
Q99566477 | Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections |
Q34237335 | Canadian clinical practice guidelines for invasive candidiasis in adults |
Q42272295 | Candida infections in solid organ transplantation |
Q42200421 | Candidaemia in patients with haematological disorders and stem cell transplant |
Q36904887 | Candidemia in the in-patient setting: treatment options and economics |
Q36158204 | Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B. |
Q34322081 | Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis |
Q33998703 | Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study |
Q37888750 | Caspofungin: when and how? The microbiologist's view |
Q35678997 | Changing strategies for the management of invasive fungal infections |
Q57364560 | Chapter 9 Interaction of Polyene Macrolide Antibiotics with Lipid Model Membranes |
Q34763371 | Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B. |
Q90737374 | Choosing the Right Antifungal Agent in ICU Patients |
Q35905124 | Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic Diseases |
Q64070463 | Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B |
Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
Q40463769 | Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. |
Q51191494 | Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. |
Q32060480 | Clinical experience with itraconazole in systemic fungal infections |
Q34546811 | Clinical hepatotoxicity associated with antifungal agents |
Q37418841 | Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea. |
Q36968140 | Clinical pharmacology of antifungal agents in pediatric patients |
Q35129039 | Clinical pharmacology of antifungal compounds |
Q51617424 | Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. |
Q34936576 | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. |
Q35917135 | Combating infections in hematopoietic stem cell transplant recipients |
Q46642455 | Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. |
Q35974333 | Combination therapy for mucormycosis: why, what, and how? |
Q34229980 | Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits |
Q34680675 | Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model |
Q38696930 | Comparison between liposomal formulations of amphotericin B. |
Q28359772 | Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial |
Q40145641 | Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial |
Q41543803 | Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. |
Q45260686 | Comparison of the effect of amphotericin B desoxycholate and amphotericin B colloidal dispersion on renal functions and renal morphology in rats |
Q34071600 | Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients |
Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
Q38284463 | Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
Q38284458 | Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. |
Q37624898 | Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment. |
Q44396642 | Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study |
Q37263911 | Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia |
Q40487519 | Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy |
Q42165120 | Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients |
Q48621980 | Cryptococcal meningitis in renal transplant patients associated with environmental exposure |
Q37079099 | Current and future therapeutic options in the management of invasive aspergillosis |
Q37030218 | Current antimicrobial usage for the management of neutropenic fever in Korea: a nationwide survey |
Q37868705 | Current issues in the clinical management of invasive aspergillosis--the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. |
Q32060457 | Current management of fungal infections. |
Q37151326 | Current options in antifungal pharmacotherapy. |
Q38115356 | Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. |
Q35019920 | Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades |
Q37157893 | Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents |
Q37833638 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies |
Q42646402 | Design of Micelle Nanocontainers Based on PDMAEMA-b-PCL-b-PDMAEMA Triblock Copolymers for the Encapsulation of Amphotericin B. |
Q36484942 | Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques |
Q51191991 | Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. |
Q89920309 | Development of Amphotericin B Micellar Formulations Based on Copolymers of Poly(ethylene glycol) and Poly(ε-caprolactone) Conjugated with Retinol |
Q40041299 | Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). |
Q37650317 | Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. |
Q38079194 | Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B. |
Q33753500 | Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). |
Q33722067 | Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B |
Q39661366 | Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus |
Q38059082 | Disorders of calcium and magnesium balance: a physiology-based approach |
Q45065480 | Drug-Induced Kidney Injury in the Elderly |
Q80378913 | Drug-induced nephrotoxicity in children: pharmacologically based prevention of long-term impairment |
Q38832223 | Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. |
Q40174281 | Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases |
Q40333474 | Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden |
Q37157379 | Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting |
Q40497071 | Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea |
Q36613885 | Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients |
Q55034381 | Editorial response: choosing amphotericin B formulations-between a rock and a hard place. |
Q46284853 | Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. |
Q46366403 | Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies |
Q57789799 | Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation |
Q40043040 | Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. |
Q30240770 | Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis. |
Q37944001 | Efficacy and safety of current drug therapies for invasive aspergillosis |
Q40313049 | Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders |
Q53271427 | Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT. |
Q44737751 | Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease |
Q36456366 | Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study |
Q43468516 | Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders |
Q28345150 | Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice |
Q33978902 | Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats |
Q40190146 | Elderly kidney transplant recipient with intermittent fever: a case report of leishmaniasis with acute kidney injury during liposomal amphotericin B therapy. |
Q34092228 | Emerging Issues in Nosocomial Fungal Infections |
Q58690890 | Emerging Technologies of Polymeric Nanoparticles in Cancer Drug Delivery |
Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
Q44638978 | Empiric antifungal therapy in neutropenic cancer patients |
Q37859365 | Empiric antifungal therapy in patients with febrile neutropenia |
Q36285521 | Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis |
Q43834926 | Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy |
Q37159577 | Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients |
Q40489288 | Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin |
Q40387020 | Empirical antifungal therapy in selected patients with persistent febrile neutropenia. |
Q40492348 | Empirical antifungal therapy in selected patients with persistent fever and neutropenia |
Q37379973 | Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan |
Q80464838 | Endophthalmitis due to Trichosporon beigelii in acute leukemia |
Q34606681 | Epidemiology of cryptococcal meningitis in the US: 1997-2009. |
Q37925096 | European expert opinion on the management of invasive candidiasis in adults |
Q46050924 | European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update |
Q43415903 | Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions |
Q52312050 | Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. |
Q38494920 | Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B. |
Q35033597 | Evidence-based guidelines for empirical therapy of neutropenic fever in Korea |
Q47263594 | Evolution and Clinical Translation of Drug Delivery Nanomaterials |
Q36130619 | Experience with community-based amphotericin B infusion therapy |
Q44738486 | Exposure of the yeast Candida albicans to the anti-neoplastic agent adriamycin increases the tolerance to amphotericin B. |
Q59230857 | Factors Associated with Severe Manifestations of Histoplasmosis in AIDS |
Q46447902 | Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation |
Q34071620 | Febrile neutropenia in allogeneic transplantation |
Q33265510 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia |
Q31372000 | Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group |
Q33253851 | Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents |
Q37739908 | Fungal infections after hematopoietic stem cell transplantation |
Q35038473 | Fungal infections in nontransplant patients with hematologic malignancies |
Q34294869 | Fungal infections in patients undergoing blood and marrow transplantation |
Q34145791 | Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment |
Q36569874 | Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience |
Q36616182 | Fungal pneumonia due to molds in patients with hematological malignancies |
Q34939981 | Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. |
Q59308866 | Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies |
Q40497134 | Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study |
Q42738330 | Galactomannan testing during mold-active prophylaxis |
Q40114699 | Gastrointestinal Mucormycosis After Orthotopic Liver Transplantation Presenting as Femoral Nerve Palsy: A Case Report and Review of the Literature |
Q91171836 | Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium |
Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
Q35746695 | Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. |
Q33420040 | Hematological toxicities associated with amphotericin B formulations |
Q37016279 | High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study |
Q79686756 | High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation |
Q38507930 | How nanotechnology-enabled concepts could contribute to the prevention, diagnosis and therapy of bacterial infections |
Q35245238 | Human Fungal Pathogens of Mucorales and Entomophthorales |
Q36217734 | Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition |
Q33748160 | Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report |
Q40263137 | Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study |
Q40481007 | Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. |
Q42946320 | Impact of the administration of liposomal amphotericin B in patients with renal function impairment at initiation of treatment |
Q27336142 | Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis |
Q40595108 | Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer |
Q35860053 | Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria |
Q46425791 | Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. |
Q35557446 | Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment |
Q44571013 | Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
Q37791930 | Infectious complications in neutropenic cancer patients |
Q34305085 | Infectious complications of febrile leukopenia |
Q34348047 | Infectious morbidity in critically ill patients with cancer |
Q40446187 | Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. |
Q44417476 | Intravenous Itraconazole followed by Oral Itraconazole for the Treatment of Amphotericin-B-Refractory Invasive Pulmonary Aspergillosis |
Q37474433 | Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. |
Q90482675 | Invasive Candidiasis in the Elderly: Considerations for Drug Therapy |
Q38066616 | Invasive aspergillosis in the intensive care unit |
Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
Q37631486 | Invasive candidiasis in pediatric intensive care units |
Q38110850 | Invasive candidiasis: update on current pharmacotherapy options and future perspectives |
Q37431764 | Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint |
Q33234912 | Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients |
Q44686777 | Invasive fungal infections in patients with hematologic malignancies: the next steps |
Q34636544 | Invasive fungal infections: evolving challenges for diagnosis and therapeutics |
Q34997741 | Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia |
Q46908044 | Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities |
Q40404772 | Is family screening necessary in brucellosis? |
Q37287794 | Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome |
Q47556262 | Leishmaniasis in humans: drug or vaccine therapy? |
Q40647609 | Lethargy and vision loss: successful management of rhinocerebral mucormycosis |
Q33723201 | Lipid amphotericin B combinations; 'la crème de la crème'? |
Q44135235 | Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia |
Q44733428 | Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients |
Q44135232 | Lipid formulations of amphotericins: are you a lumper or a splitter? |
Q33656455 | Lipid-based amphotericin B formulations: from animals to man. |
Q34204648 | Lipid-based amphotericin B: a review of the last 10 years of use. |
Q46373110 | Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient |
Q36868273 | Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions |
Q45223612 | Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. |
Q28298468 | Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) |
Q50793077 | Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. |
Q43871855 | Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study |
Q46946844 | Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). |
Q34960317 | Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections |
Q36140647 | Liposomal amphotericin B: clinical experience and perspectives |
Q44033190 | Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model |
Q37476694 | Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature |
Q35592009 | Localised invasive sino-orbital aspergillosis: characteristic features |
Q58852071 | Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation |
Q40536892 | Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial |
Q34280580 | Management of Candida species infections in critically ill patients |
Q58791971 | Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations |
Q38087195 | Management of chemotherapy-induced neutropenic fever |
Q37909774 | Management of fungal lung disease in the immunocompromised. |
Q35675979 | Management of infectious complications in the hematopoietic stem cell transplant recipient |
Q35904821 | Management of invasive candidiasis in critically ill patients |
Q36087577 | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients |
Q40533942 | Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia |
Q34775518 | Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study |
Q40241173 | Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study. |
Q40790252 | Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation. |
Q56970523 | Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial |
Q37738437 | Modern antifungal therapy for neutropenic fever |
Q40401842 | Modern antifungal therapy for neutropenic fever |
Q34071591 | Modifications of therapy |
Q37765079 | Modified intention to treat reporting in randomised controlled trials: systematic review |
Q32068576 | Mortality and costs of acute renal failure associated with amphotericin B therapy |
Q43681152 | Mortality rates in comparative trials of formulations of amphotericin B. |
Q34443147 | Mucormycoses |
Q37098160 | Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? |
Q37401889 | NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency |
Q38628767 | Nanomedicine for Infectious Disease Applications: Innovation towards Broad-Spectrum Treatment of Viral Infections. |
Q34230175 | Nanopharmaceuticals (part 1): products on the market |
Q36441428 | Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. |
Q56837353 | Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses |
Q43712238 | Nephrotoxicity of amphotericin B desoxycholate |
Q35627629 | New and emerging antifungal agents: impact on respiratory infections |
Q45006383 | New antifungal agents and bronchopulmonary mycoses |
Q38797864 | New facets of antifungal therapy |
Q36491819 | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations |
Q49803837 | Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences |
Q46840248 | Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin |
Q35220799 | Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment? |
Q50112710 | Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults |
Q37178176 | Optimizing efficacy of Amphotericin B through nanomodification. |
Q36920328 | Optimizing efficacy of amphotericin B through nanomodification |
Q37043539 | Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia |
Q90470137 | Orbital apex syndrome secondary to aspergilloma masquerading as a paranasal sinus tumor: A case report and literature review |
Q36425955 | Orbital mucormycosis in an immunocompetent individual. |
Q35756513 | Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination |
Q39883914 | Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia |
Q37260918 | Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups |
Q36163786 | PEGylated Phospholipid Micelle-Encapsulated Near-Infrared PbS Quantum Dots for in vitro and in vivo Bioimaging |
Q50448386 | PEGylated liposomes associate with Wnt3A protein and expand putative stem cells in human bone marrow populations |
Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
Q42255047 | Persistent hypokalemia in an acute lymphoblastic leukemia patient |
Q35385786 | Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus |
Q40455545 | Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. |
Q36759440 | Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia |
Q38073334 | Pharmacoeconomic assessment of therapy for invasive aspergillosis |
Q38097528 | Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients |
Q37820674 | Pharmacoeconomics of voriconazole in the management of invasive fungal infections |
Q34045435 | Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis |
Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
Q34113512 | Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans |
Q34352014 | Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection |
Q33232599 | Pharmacological advances in the treatment of invasive candidiasis |
Q36176371 | Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin |
Q37732209 | Pharmacologically-induced metabolic acidosis: a review. |
Q64070471 | Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections |
Q34768471 | Pharmacotherapy of Candida bloodstream infections: new treatment options, new era. |
Q34113525 | Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate |
Q82364250 | Polymerase chain reaction screening for fungemia and/or invasive fungal infections in patients with hematologic malignancies |
Q37428678 | Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children |
Q36276870 | Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens |
Q24542404 | Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases |
Q39575509 | Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. |
Q40344144 | Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation |
Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
Q32052950 | Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients |
Q34460523 | Practice guidelines for the diagnosis and management of skin and soft-tissue infections |
Q33894467 | Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America |
Q92782666 | Pre-emptive versus empirical antifungal therapy in immunocompromised children |
Q33371455 | Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry |
Q64070466 | Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B |
Q34511403 | Prevention of acute renal failure in the critically ill. |
Q58772822 | Primary Oral Mucormycosis Due to Rhizopus microsporus after Allogeneic Stem Cell Transplantation |
Q37657464 | Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? |
Q35959480 | Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature |
Q36248701 | Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy |
Q44017071 | Pulmonary aspergillosis: diagnosis and treatment |
Q36194915 | Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. |
Q33974908 | Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia. |
Q34350416 | Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management |
Q34151170 | Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. |
Q35917383 | Recent advances in antifungal pharmacotherapy for invasive fungal infections |
Q24642450 | Recent advances in the management of mucormycosis: from bench to bedside |
Q58477139 | Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp |
Q26824260 | Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1) |
Q38114270 | Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network. |
Q93609063 | References |
Q40562194 | Release of prostaglandin E-2 in bovine brain endothelial cells after exposure to three unique forms of the antifungal drug amphotericin-B: role of COX-2 in amphotericin-B induced fever |
Q38236893 | Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? |
Q46674198 | Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone |
Q64131314 | Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: una visión multidisciplinar |
Q40175242 | Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies |
Q34098069 | Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis |
Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
Q38077678 | Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. |
Q35799730 | Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients |
Q44925292 | Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis |
Q40454115 | Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. |
Q35715408 | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
Q40271090 | Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia |
Q33977852 | Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. |
Q73203964 | Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs |
Q37613070 | Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients |
Q45985382 | Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. |
Q33983629 | Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study |
Q73755560 | Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats |
Q87393334 | Section 3: Prevention and Treatment of AKI |
Q87393341 | Section 4: Contrast-induced AKI |
Q33980413 | Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis |
Q35200641 | Specific infectious complications after stem cell transplantation |
Q34071594 | Standard antifungal therapy in neutropenic patients |
Q46881807 | Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial |
Q34724824 | Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times |
Q37473671 | Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea |
Q43115263 | Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug |
Q43808662 | Successful treatment of invasive mould infection affecting lung and brain in an adult suffering from acute leukaemia |
Q47230940 | Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation |
Q40247785 | Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B. |
Q44516857 | Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction |
Q33876645 | Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. |
Q35585219 | Systemic Antifungal Therapy: New Options, New Challenges |
Q44606392 | Systemic antifungal agents |
Q55437393 | T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications. |
Q34848032 | The Pathophysiology and Treatment of Candida Sepsis |
Q32060501 | The cost of treating systemic fungal infections |
Q43797281 | The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy |
Q36264982 | The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis |
Q46593127 | The hepatotoxicity of antifungal medications in bone marrow transplant recipients |
Q36344173 | The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy |
Q43600554 | The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylax |
Q35193749 | The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. |
Q37800610 | The value of amphotericin B in the treatment of invasive fungal infections |
Q44498477 | Therapeutic Approach to Candida Sepsis. |
Q34214827 | Therapy for fungal infections in leukemia |
Q40222438 | Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens |
Q34022479 | Towards a targeted, risk-based, antifungal strategy in neutropenic patients |
Q33409652 | Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. |
Q34228354 | Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin |
Q34590013 | Treatment of documented and suspected neutropenia-associated invasive fungal infections |
Q34667166 | Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update |
Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
Q38056762 | Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials |
Q37170218 | Treatment of invasive candidiasis in the elderly: a review |
Q37469829 | Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
Q34273629 | Treatment of systemic fungal infections in older patients: achieving optimal outcomes |
Q37863921 | Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? |
Q40800105 | Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party |
Q44440957 | Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics |
Q33852973 | Tuftsin-bearing liposomes in treatment of macrophage-based infections. |
Q35794490 | Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach |
Q45017863 | Update on antifungal treatment of invasive Candida and Aspergillus infections |
Q61832641 | Update on invasive fungal infections: the last two years |
Q43191432 | Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine |
Q37785548 | Updated guidelines for managing fungal diseases in hematology patients |
Q36364856 | Use of antifungal drugs in hematology |
Q43839758 | Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis |
Q44589171 | Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience |
Q33946021 | Voriconazole: the newest triazole antifungal agent |
Q33712955 | Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study |
Q73230080 | [Invasive fungal infections in patients with hematological malignancies: a clinical approach] |
Q32105170 | [New lipid formulations of amphotericin B. Review of the literature]. |
Search more.